Valeo Financial Advisors LLC Takes Position in Humacyte, Inc. $HUMA

Valeo Financial Advisors LLC acquired a new stake in Humacyte, Inc. (NASDAQ:HUMA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 15,400 shares of the company’s stock, valued at approximately $32,000.

A number of other large investors have also bought and sold shares of the stock. Wealth Effects LLC grew its holdings in Humacyte by 5.8% in the second quarter. Wealth Effects LLC now owns 102,167 shares of the company’s stock worth $214,000 after purchasing an additional 5,600 shares during the period. MetLife Investment Management LLC boosted its position in shares of Humacyte by 14.4% during the 1st quarter. MetLife Investment Management LLC now owns 51,442 shares of the company’s stock worth $88,000 after purchasing an additional 6,482 shares in the last quarter. XTX Topco Ltd raised its stake in Humacyte by 22.5% during the 1st quarter. XTX Topco Ltd now owns 53,797 shares of the company’s stock worth $92,000 after buying an additional 9,868 shares during the period. Lazari Capital Management Inc. acquired a new position in Humacyte during the 2nd quarter worth approximately $27,000. Finally, Pallas Capital Advisors LLC acquired a new position in Humacyte during the 2nd quarter worth approximately $42,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Trading Down 4.9%

NASDAQ HUMA opened at $1.56 on Friday. Humacyte, Inc. has a 12 month low of $1.15 and a 12 month high of $6.77. The company has a current ratio of 2.45, a quick ratio of 1.93 and a debt-to-equity ratio of 2.97. The firm has a market capitalization of $247.06 million, a P/E ratio of -3.47 and a beta of 1.89. The business has a fifty day simple moving average of $1.73 and a 200 day simple moving average of $1.93.

Humacyte (NASDAQ:HUMA) last posted its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.94 million. On average, analysts predict that Humacyte, Inc. will post -1.27 EPS for the current fiscal year.

Analyst Ratings Changes

HUMA has been the subject of several recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Wednesday. Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, August 17th. Barclays initiated coverage on shares of Humacyte in a research note on Wednesday, August 27th. They issued an “overweight” rating and a $3.50 price objective on the stock. TD Cowen dropped their price objective on shares of Humacyte from $5.00 to $3.50 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Finally, D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Monday, October 6th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.29.

Insider Activity at Humacyte

In related news, CEO Laura E. Niklason sold 1,100,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the completion of the sale, the chief executive officer directly owned 591,685 shares of the company’s stock, valued at approximately $964,446.55. This trade represents a 65.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brady W. Dougan sold 1,100,000 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total value of $1,793,000.00. Following the completion of the transaction, the director owned 591,685 shares of the company’s stock, valued at $964,446.55. This trade represents a 65.02% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,482,090 shares of company stock worth $7,466,382. Insiders own 5.10% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.